Patent: 10,035,838
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Summary for Patent: 10,035,838
| Title: | Immunotherapy against melanoma and other cancers |
| Abstract: | The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. |
| Inventor(s): | Sonntag; Annika (Tuebingen, DE), Weinschenk; Toni (Aichwald, DE), Mahr; Andrea (Tuebingen, DE), Schoor; Oliver (Tuebingen, DE), Fritsche; Jens (Dusslingen, DE), Singh; Harpreet (Houston, TX) |
| Assignee: | IMMATICS BIOTECHNOLOGIES GMBH (Tuebingen, DE) |
| Application Number: | 15/489,399 |
| Patent Claims: | see list of patent claims |
Details for Patent 10,035,838
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Genentech, Inc. | AVASTIN | bevacizumab | Injection | 125085 | 02/26/2004 | See Plans and Pricing | 2036-04-21 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
